Tagrisso Chemotherapy Combo Achieves Significan...

By João L. Carapinha

July 28, 2025

The FLAURA2 Phase III trial's final analysis confirms that the Tagrisso chemotherapy combo improves overall survival (OS) in untreated patients with EGFR-mutated NSCLC. This combination of osimertinib with pemetrexed and platinum-based chemotherap...
Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical ...
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
Biosimilar Clinical Approach
Efficacy of Ultomiris Pediatric TMA Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies